BPC-157: Tissue Repair Peptide Research Guide

BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide comprising 15 amino acids (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val). It is derived from a sequence found in the gastric juice protein BPC and has been extensively studied in preclinical research for its cytoprotective and regenerative properties.

First described in the 1990s by researchers at the University of Zagreb, BPC-157 has since accumulated a substantial body of animal study literature covering musculoskeletal repair, gastrointestinal mucosal healing, angiogenesis, and neuroprotection. It has no approved therapeutic application — all available material is for laboratory research use only.

BPC-157 exerts its effects through multiple converging pathways identified in preclinical studies:

• VEGF upregulation — BPC-157 promotes vascular endothelial growth factor expression, driving angiogenesis and improved vascularisation of healing tissue
• Nitric oxide pathway modulation — studies suggest BPC-157 influences both eNOS and nNOS signalling, contributing to vasodilation and tissue perfusion in healing models
• Growth factor receptor expression — upregulation of EGF receptor (EGFR) and related growth factor pathways has been documented in tendon and gut tissue models
• Fibroblast migration and proliferation — in vitro studies show enhanced fibroblast activity, central to connective tissue repair
• FAK/paxillin pathway — BPC-157 has been shown to activate focal adhesion kinase signalling, important in cell migration and extracellular matrix organisation

This multi-pathway activity profile makes BPC-157 a versatile tool for investigating tissue repair mechanisms across different model systems.

The largest body of BPC-157 preclinical literature concerns tendon, ligament, and muscle repair. Studies by Pevec et al. and the Zagreb group demonstrated significantly accelerated Achilles tendon repair in rat transection models, with BPC-157-treated animals showing improved histological organisation and functional recovery timelines.

Ligament repair studies have similarly shown enhanced collagen organisation in medial collateral and anterior cruciate ligament injury models. The proposed mechanism involves both direct fibroblast stimulation and improved local vascularisation supplying the healing site. Bone healing studies have extended these findings to fracture models, where BPC-157 administration was associated with faster callus formation.

BPC-157's name derives from its origin in gastric juice BPC — and its gastrointestinal effects are among its most replicated findings. Studies in rodent models have examined its protective and healing effects on:

• Gastric ulcers (NSAID-induced, ethanol-induced, and stress-induced models)
• Intestinal anastomosis healing and fistula repair
• Inflammatory bowel disease models (TNBS and DSS-induced colitis)
• Short bowel syndrome (intestinal adaptation studies)

Cytoprotective effects are thought to involve both mucosal defence upregulation and angiogenic stimulation of mucosal vasculature. BPC-157 has also shown hepatoprotective effects in models of liver injury from toxins including ethanol and paracetamol.

RetaLABS BPC-157 is supplied as lyophilised powder. Recommended reconstitution protocol:

• Add bacteriostatic water slowly along the vial wall — do not inject directly onto the powder cake
• Gently swirl until fully dissolved — do not shake or vortex
• Typical research concentration: 1–2mg/mL
• Store lyophilised vials at −20°C, protected from light
• Reconstituted solution: refrigerate at 2–8°C, use within 4 weeks
• Avoid repeated freeze-thaw cycles

For detailed reconstitution guidance, see the Peptide Reconstitution & Storage Guide.

RetaLABS BPC-157 is sourced from manufacturers supplying a Certificate of Analysis (COA) with each batch. The COA documents compound identity, purity by HPLC, and lot-specific test results. COAs are available on request.

Both the BPC-157 20mg vial and the BPC-157 / TB-500 Blend are available for researchers investigating single-compound or combination protocols. All products are supplied for laboratory research use only and are not approved for human therapeutic use.